Claims for Patent: 8,354,516

Summary for Patent: 8,354,516

Title:	Polypeptide producing cells
Abstract:	The current invention describes a nucleic acid comprising in a 5\' to 3\' direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5\' splice donor site and terminated by a 3\' splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
Inventor(s):	Endl; Josef (Weilheim, DE), Kopetzki; Erhard (Penzberg, DE), Ploettner; Oliver (Munich, DE), Schwarz; Ursula (Bichl, DE), Tiefenthaler; Georg (Sindelsdorf, DE)
Assignee:	Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:	12/299,918
Patent Claims:	1. A nucleic acid comprising in a 5' to 3' direction a) a first nucleic acid encoding an immunoglobulin heavy chain without an in frame stop codon at its 3' terminus , b) a second nucleic acid beginning with a 5' splice donor site and terminated by a 3' splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal of a human or mouse immunoglobulin .alpha., .epsilon., .gamma. and .mu. heavy chain, and c) a third nucleic acid encoding at least 60% of a complete human immunoglobulin transmembrane domain, wherein said immunoglobulin heavy chain and a marker are expressed from the same nucleic acid, wherein the marker is a plasma-membrane bound form of the expressed immunoglobulin heavy chain. 2. The nucleic acid of claim 1, characterized in that said second nucleic acid comprises only one 5' splice donor site and only one 3' splice acceptor site. 3. The nucleic acid of claim 2, characterized in that said second nucleic acid is a germline-derived immunoglobulin heavy chain intron, wherein in said intron 50consecutive nucleotides are deleted. 4. The nucleic acid of claim 1, characterized in that said first nucleic acid encodes an human immunoglobulin heavy chain comprising all exons and all but one intron of the genomically organized immunoglobulin heavy chain gene. 5. An isolated eukaryotic cell comprising a nucleic acid according to claim 1. 6. The eukaryotic cell according to claim 5, characterized in that said eukaryotic cell is selected from the group consisting of CHO cells, NSO cells, Sp2/0 cells, COS cells, K562 cells, BHK cells, PER.C6.RTM. cells, and HEK cells. 7. A method for selecting a eukaryotic cell expressing an immunoglobulin heavy chain, whereby the method comprises a) transfecting a eukaryotic cell with a nucleic acid comprising in a 5' to 3' direction i) a first nucleic acid encoding a immunoglobulin heavy chain without an in frame translational stop codon, ii) a second nucleic acid beginning with a splice donor site and terminated by a splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, iii) a third nucleic acid encoding at least 60% of a complete immunoglobulin transmembrane domain, b) culturing of said transfected cell under conditions suitable for the production of pre-mRNA from said nucleic acid, processing of said pre-MRNA, and translation of said processed mRNA into a polypeptide, wherein said transfected cell produces soluble immunoglobulin heavy chain and plasma-membrane-bound immunoglobulin heavy chain by alternative splicing of said pre-mRNA, and c) selecting a cell with plasma-membrane-bound immunoglobulin heavy chain to be said cell expressing an immunoglobulin heavy chain. 8. The method of claim 7, characterized in that i) said first nucleic acid encodes at least 60% of an immunoglobulin heavy chain C.sub.H3 or C.sub.H4 domain, ii) said second nucleic acid is beginning with the 5' splice donor site of an immunoglobulin heavy chain C.sub.H3 or C.sub.H4 domain exon and is terminated by the 3' splice acceptor site of the immunoglobulin heavy chain transmembrane domain exon M1, iii) said third nucleic acid comprises at least 60% of an immunoglobulin transmembrane domain. 9. The method of claim 7, characterized in that said second nucleic acid is obtained from the nucleic acid encoding a polypeptide or protein selected from the group consisting of the C3b/C4b receptor; human, chicken, and rat EGFR; FGFR; human and mouse immunoglobulin .alpha., .epsilon., .gamma.. .mu. heavy chain; human PLA.sub.2 receptor; chicken Cek5; and mouse leukemia inhibitory factor receptor .alpha.-chain. 10. The method of claim 7, characterized in that only one intron of the produced pre-mRNA can be spliced alternatively. 11. The method of claim 10, characterized in that said selecting a cell is performed by a method selected from the group consisting_of flow cytometry, ELISA, immunoprecipitation, immunoaffinity column chromatography, magnetic bead imunoafflinity sorting, microscopy-based isolation methods, or immunological binding. 12. The method of claim 11, characterized in that the 5' splice site is an alternatively spliceable nucleic acid, resulting in a molecular ratio of soluble polypeptide to plasma-membrane-bound polypeptide of from more than 50:50 to less than 100:0.

Details for Patent 8,354,516

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2026-05-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2026-05-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2026-05-17